StockGuide AI
Suivre des actions
EN RU ES DE IT PT FR
GSK

GSK

Prix: 53.04

Entreprise et modèle économique

GSK is a global healthcare company focused on pharmaceuticals, vaccines, and consumer healthcare products. Its core products include prescription medications for various therapeutic areas, vaccines for infectious diseases, and over-the-counter consumer health products. Major business segments consist of Pharmaceuticals, Vaccines, and Consumer Healthcare, with revenue primarily generated from prescription drugs and vaccines. The company aims to address health challenges through innovation and research.

Profil d’investissement

GSK's stock presents a neutral investment profile, appealing to investors seeking a balance between growth and dividends. The company offers a moderate dividend yield, which may attract income-focused investors, while its pharmaceutical innovations suggest potential for future growth. However, recent revenue declines indicate caution for growth-oriented investors. Overall, it may suit those looking for stability rather than aggressive growth.

Site officiel

Métriques fondamentales (expérimental)

BPA (TTM) — bénéfice par action des 12 derniers mois, $
3.42 OK
Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
-11.5% ↓
Surprise BPA
6.9% meilleur que prévu
Volatilité 20 j
1.5% stable
Rendement du dividende
3.5% modéré dernière date ex-dividende: 2026-05-15
Données FMP / FinFeed mises à jour: 2026-06-10
Reco: Acheter Potentiel: 63 Risque: 42 Mis à jour: 2026-06-13 02:53
Comment fonctionne la recommandation
Pourquoi l’IA pense cela:
Stable dividend, but revenue decline raises concerns.

Suivre dans le portefeuille

Graphique des prix

Recommandation IA Prévision d’analyste Événement calendrier Signal positif Signal négatif Neutre / mise à jour Conserver / informatif B My buy S My sell
Changements de recommandation IA
Date Avant Après Raison
2026-06-13 02:53 Conserver Acheter Stable dividend, but revenue decline raises concerns.
2026-05-28 02:46 Vendre Conserver Weak fundamentals and mixed momentum signal caution.
2026-05-20 02:45 Conserver Vendre Weak fundamentals and negative momentum raise concerns.
Prévisions des analystes
Date Analyste Action Objectif Prix alors
2025-10-30 11:27 CFRA Mettre à jour — → 53 46.67
J.M. Smucker Company Micron Technology GSK Alibaba Vail Resorts Qualcomm

Stocks to Watch: Nuvalent Soars on GSK Acquisition Announcement, J.M. Smucker Reports Strong Earnings, SailPoint Issues Weak Guidance

06/09/2026, 05:33 AM business review J.M. Smucker Company Micron Technology GSK Alibaba Vail Resorts Qualcomm
Nuvalent's shares surged nearly 39% following GSK's announcement of a $10.6 billion acquisition, highlighting significant market activity in the pharmaceutical sector. Meanwhile, J.M. Smucker's strong earnings report positively impacted its stock, while SailPoint's disappointing guidance led to a notable decline in its shares.